MCLA-145 monotherapy and in combination with pembrolizumab rapid oral session presentation: June 2, 2024, 11:30 a.m.-1:00 p.m. CT MCLA-129 in NSCLC with c-MET exon 14 skipping mutations poster ...
LONG BEACH, Calif.--(BUSINESS WIRE)--The Beauty Health Company (NASDAQ:SKIN), home to flagship brand Hydrafacial™, announced today that a video poster abstract presentation on the efficacy and safety ...
Autonomix Medical's research on treating pancreatic cancer pain has been accepted for presentation at the SIO 2025 Annual Meeting. Autonomix Medical, Inc. has announced that its abstract has been ...
Oral presentation of investigator-initiated Phase 2 study evaluating ZYNLONTA ® (loncastuximab tesirine-lpyl) in combination with rituximab in patients with r/r follicular lymphoma Poster presentation ...
You must submit your abstract using the online submission form. Abstracts sent by email will not be considered. Abstracts that are incomplete will not be considered. All ESA Annual Meeting proposal ...
For more and to view the abstract, visit the AACR Annual Meeting website. As previously announced, on December 11, 2024, TuHURA entered into a definitive agreement with Kineta, Inc. (OTC Pink: KANT) ( ...
International Conference on Advances in Radiation Oncology (ICARO-4) - Abstract and Paper Submission
The purpose of the event is to discuss and define the current role and future potential of technological, medical physics and molecular/biological innovations for routine clinical practice in ...
Market fluctuations impacting supply chains. Political support: policies and strategies. Expansion of conversion enrichment and fuel fabrication facilities to meet growing demand. Technological ...
This acceptance marks the fifth major medical conference this year to feature bexmarilimab in an oral session, reinforcing the drug's unique mechanism in hematologic malignancies and potential to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback